表紙
市場調査レポート

EpiCast Report:糖尿病性腎症の疫学予測

EpiCast Report: Diabetic Nephropathy - Epidemiology Forecast to 2022

発行 GlobalData 商品コード 290459
出版日 ページ情報 英文 39 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
EpiCast Report:糖尿病性腎症の疫学予測 EpiCast Report: Diabetic Nephropathy - Epidemiology Forecast to 2022
出版日: 2013年11月30日 ページ情報: 英文 39 Pages
概要

糖尿病患者数の世界的な増加に伴い、糖尿病性腎症は慢性腎疾患の中で最も一般的な疾患とされています。主要7カ国(米国、フランス、ドイツ、イタリア、スペイン、英国、日本)における糖尿病性腎症の患者総数は、2012年には1400万でしたが、その後年率4.16%で増加し、2022年には1980万になると予測されています。

当レポートは、世界の主要7ヶ国における糖尿病性腎症について、年齢、性別、また高血圧症を併発している糖尿病患者数のセグメントごとに予測を行っており、危険因子の概要と7カ国における疫学的な動向をまとめ、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
    • 血糖コントロールの悪さが糖尿病性腎症のリスクを高める
  • 世界の動向
    • 米国
    • EU5カ国
    • 日本
  • 糖尿病性腎症の疫学予測
    • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
  • 糖尿病性腎症の疫学予測
    • 予測の前提および手法、糖尿病と診断された患者数
    • 予測の前提および手法-糖尿病性腎症
  • 糖尿病性腎症の疫学予測
    • 糖尿病性腎症の患者総数
    • 患者総数:年齢別
    • 患者総数:性別
    • 糖尿病性腎症のうち高血圧を併発している患者総数
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

目次
Product Code: GDHCER052

With the increasing prevalence of diabetes around the world, diabetic nephropathy is the most common type of chronic kidney disease (KDOQI, 2007; Zimmet et al., 2001). When uncontrolled diabetes persists for 15 to 25 years, the blood vessels in the kidneys are damaged, resulting in abnormal amounts of proteins, including albumin, leaking into the urine (ADA, 2013; CDA, 2012; NHS, 2011; NKUDIC, 2013). Because diabetic nephropathy is a complication of diabetes, and at least 90% of all diabetic cases are type 2 diabetes, the risk factors and common comorbidities for type 2 diabetes are also considered to be the same for diabetic nephropathy. The major risk factors for type 2 diabetes are family history, advancing age, obesity, and gestational diabetes. Hypertension and dyslipidemia are also the most commonly-occurring comorbidities in people with diabetic nephropathy (GlobalData, 2013b).

According to GlobalData's forecast, the 7MM had 4,889,171 prevalent cases of diabetic retinopathy in 2012. There were 14.03 million total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in the 7MM, there will be 19.87 million total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in the 7MM by 2022, with an annual growth rate (AGR) of 4.16% during the forecast period.

Scope

  • The diabetic nephropathy EpiCast Report provides an overview of the risk factors and epidemiological trends for diabetic nephropathyin the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the total prevalent cases of diabetic retinopathy in the diagnosed diabetic population segmented by age, (over 40 years of age) and sex. The diagnosed prevalent cases are then further segmented by the presence of comorbid hypertension.
  • The diabetic nephropathy epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global diabetic nephropathy market.
  • Quantify patient populations in the global diabetic nephropathy market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for diabetic nephropathy therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. Poor glycemic control elevates the risk of diabetic nephropathy
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Epidemiological Forecast for Diabetic Nephropathy (2012-2022)
    • 3.4.1. Forecast Methodology
    • 3.4.2. Sources Used
    • 3.4.3. Sources Not Used
  • 3.5. Epidemiological Forecast for Diabetic Nephropathy (2012-2022)
    • 3.5.1. Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Diabetes
    • 3.5.2. Forecast Assumptions and Methods - Diabetic Nephropathy
  • 3.6. Epidemiology Forecast for Diabetic Nephropathy (2012-2022)
    • 3.6.1. Total Prevalent Cases of Diabetic Nephropathy
    • 3.6.2. Total Prevalent Cases of Diabetic Nephropathy by Age
    • 3.6.3. Total Prevalent Cases of Diabetic Nephropathy by Sex
    • 3.6.4. Total Prevalent Cases of Comorbid Hypertension in Total Diabetic Nephropathy
  • 3.7. Discussion
    • 3.7.1. Epidemiological Forecast Insight
    • 3.7.2. Limitations of the Analysis
    • 3.7.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Health Policy
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Classification of Patients Based on the Levels of Albuminuria for the Three Standard Tests
  • Table 2: 7MM, Sources of the Total Prevalence Data Used in the Analysis of Diabetic Nephropathy
  • Table 3: 7MM, Sources Excluded from the Analysis of Diabetic Nephropathy
  • Table 4: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, Ages ≥40 Years, N, 2012-2022
  • Table 5: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, by Age, N, Row (%), 2012
  • Table 6: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, by Sex, Ages ≥40, N, Row (%), 2012

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, Ages ≥40 Years, N, 2012-2022
  • Figure 2: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, Both Sexes, by Age, N, 2012
  • Figure 3: 7MM, Total Prevalent Cases of Diabetic Nephropathy in the Diagnosed Diabetic Population, by Sex, Ages ≥40 Years, N, 2012
  • Figure 4: 7MM, Total Prevalent Cases of Comorbid Hypertension in Total Prevalent Cases of Diabetic Nephropathy, Both Sexes, Ages ≥40 Years, N, 2012
Back to Top